The da Vinci replaces keyhole and open surgery with instruments that bend at the tip, which a surgeon drives from a console.
The company · 2 · What exactly does it sell?
Instruments used per operation lead
Each $1 of sales, 2025
60%25%16%
Instruments per operationRobotsService
Hospitals buy the robot once and buy instruments for every operation.
The company · 3 · How does it make money?
The robot once, instruments every operation
About $1,830of instruments per operation
+14%operations worldwide
3% to 5%price cut from 2027
Each robot installed brings years of instrument and service sales.
Is it a good business? · 4 · What gives it an edge?
Once bought, the robot locks in its instruments
76.3%
of revenue from instruments and service, June quarter
2024
a court found monopoly power, then withdrew it
Each instrument stops after a set number of uses, and leaving means writing off the machine and retraining the team.
Is it a good business? · 5 · What is the catch?
Rivals attack from three sides
MedtronicHugo robot cleared for urology
J&Jfiled its Ottava robot
Restore Roboticsrebuilds Intuitive's own instruments
Listed rivals: MDT · JNJ
Rebuilt instruments go straight after the recurring revenue the robot earns.
Is it a good business? · 6 · What does its record show?
Revenue doubled with profit steady
Sales, $B
5.7
6.2
7.1
8.4
10.1
11.6
Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025last 12 mo
Sales$5.71B → $11.6Brevenue, 2021 to the past year
Profit32% → 28%operating profit per $1
Kept69% → 67%kept per $1 after making it
Lower selling costs were offset by research and a thinner share kept per sale, on mix and tariffs.
Is it a good business? · 7 · How much room is there to grow?
The count misses much of the market
About $3.92Ba year from US inpatient robotic operations
$4.72Bits US instrument sales already
15.1%robotic share last measured, Michigan
Outpatient operations and new uses push the real market well beyond that count.
Is it a good business? · 8 · Who is in charge?
An engineer with 30 years there took over
July 2025Dave Rosa became chief executive
2022Jamie Samath took over finance
Gary Guthartthe former chief, now full-time chair
Guthart, who ran it before, stays on as full-time chair.
The story right now · 9 · Why do hospitals use surgical robots?
Robots make keyhole surgery easier
3.15 millionda Vinci operations, 2025
+14%operation growth
+10%US growth, slowest in years
Robots let surgeons do through small cuts what once needed open surgery, so patients recover faster. Growth abroad is fast; the US is maturing.
The story right now · 10 · Can volume make up the price cut?
More operations must offset cheaper instruments
Instrument prices cut3% to 5% from 2027.
Revenue per operation fallsBy that much.
Needs 3.1% to 5.3% moreOperations to offset.
US growth slowedTo 10%.
The cut is smaller than the 7% of the 2020 programme, but the reason for it sits in a court docket and the regulator's clearances.
The story right now · 11 · What changed lately?
Revenue up 22%, the price cut sized
$3.00adjusted profit per share, beat
+14%da Vinci operations
+10%US operations, slowing
$450Mto settle the hospital class action
Mixed quarter
American operations grew only 10%, below our line, so the test read against us.
The story right now · 12 · What is everyone arguing about?
Insurance losses, or its own price cut?
Many investors think
Lost health insurance will slow paid operations
We think
Its own price cut and slower US growth matter more
We would be wrong if US operations speed back up and more operations outrun the cut.
The price and our view · 13 · What is a share worth?
The price sits far above our value
$213what we think a share is worth · the last close is of that
$213our value
Attractive below $170
Neutral
Unattractive above $256
$119gloomy: growth halves, less kept per $1
$213our estimate: experts' path, then slowing
$279sunny: growth beats the forecast by a quarter
Value per share in three futures. None is a prediction of the share price.
We estimate what a share is worth from the cash the business should earn over many years. Our rule: buy only when the price is at least a fifth below our estimate, as a cushion for being wrong.
The price and our view · 14 · How could we be wrong?
A deeper price cut is the biggest risk
A deeper cutBiggest
Above 5% of revenue.
Slower US growthShowing now
Down to 10%.
Rebuilt instrumentsWatch
Cleared and selling.
What the cut isUnknown
China's share unsplit.
Rival robots and the courts could each push prices lower again.
The price and our view · 15 · How will we know?
January brings the 2027 forecast
US operations speed back upGood sign
Price cut held at 3% to 5%Good sign
Rebuilt instruments spreadBad sign
JAN 202728
Fourth-quarter 2026 results and the 2027 forecast, 28 January. Companies report every three months; each report is a test of the story.
Our view also changes on price alone: if the shares fall to within a fifth of our estimate, we move to Neutral.
The price and our view · 16 · So, what do we think?
An excellent business, priced as though little changes
$213our value
Attractive below $170
Neutral
Unattractive above $256
UnattractiveHigh conviction
Intuitive makes the da Vinci surgical robot, and hospitals buy its instruments for every operation. But it will cut instrument prices from 2027, US operations grew only 10% last quarter and rebuilt instruments compete.
↑ ↓ to move · C for contents
What it does
More about the company
Who it is
In keyhole surgery the surgeon works through small cuts with long rigid tools that cannot bend at the tip, so stitching at awkward angles is hard. The da Vinci puts wristed instruments on robotic arms, driven from a console beside the patient.
It is replacing both that and open surgery: robotic operations rose from 1.8% to 15.1% of general surgery in Michigan hospitals between 2012 and 2018. About 3.15 million operations were done on da Vinci systems in 2025.
How it makes money
The machine is sold or leased once. Then every operation uses about $1,830 of Intuitive's instruments, each licensed for a set number of uses before it stops working, and the hospital pays for servicing. Instruments and service were 76.3% of revenue in the June 2026 quarter: money that arrives with each operation, not with each machine.
Growth and profit
What growth costs
Growth has not made Intuitive more profitable lately. Selling and running the company take a smaller slice of each sale, and the big building programme is finished, but research takes a slightly bigger slice and each sale keeps a little less after making the product. The two roughly cancel out, so the margin is about where it was five years ago.
Its record
The numbers
Is it growing?Steady
Sales grew 20% over the twelve months to Sep 2026, about the same pace as the 21% in the year to Dec 2025.
Is it profitable?Strong
Operating margin is 28%, up from 25% in the year to Dec 2023.
Does growth pay off?Flat
Running costs take 39¢ of each sales dollar, up from 37¢ in the year to Dec 2021.
Does it earn good returns?Decent
Each dollar put into the business earns 16% a year after tax, about where it was (15%) in the year to Dec 2021.
Is it making cash?Strong
It turned 31% of sales into free cash, $3.60B over the last twelve months.
How steady is it?Uneven
Yearly sales growth has ranged from +9.0% to +31% over the last 5 years.
Are shares being diluted?Stable
The share count fell 3.9% in 4.8 years, and pay in shares costs 7.3% of sales.
Why it wins
The evidence
Once a hospital owns a da Vinci and has trained its surgeons, it buys its instruments from Intuitive, whose system counts each one's uses. Leaving means writing off the machine and retraining the team.
Outsiders have tested that grip. A federal court ruled in 2024 that Intuitive held monopoly power over replacing its instruments, then withdrew the finding. For the hospital the price is small against what goes wrong in surgery: $1,830 an operation, against about $30,000 added by one surgical infection.
Who could beat it
The rivals in full
Rivals attack from three sides. Medtronic's Hugo robot was cleared for urology in December 2025, and Johnson & Johnson has filed its Ottava robot for upper-abdominal surgery. Restore Robotics is cleared to rebuild Intuitive's own instruments, going after the instruments without touching the robot. And obesity drugs are removing some patients altogether: weight-loss operations on da Vinci are falling.
Each rival
Medtronic's Hugo robotic-assisted surgery systemMDT
The hospital stops buying a da Vinci for urology cases and buys Hugo instead - and with it Medtronic's own instruments, which is the recurring revenue rather than the machine. Medtronic already sells that hospital the stapling and energy devices, so the instrument relationship exists before the robot arrives.
Johnson & Johnson's Ottava robotic surgical systemJNJ
The hospital's general surgery robotic caseload in the upper abdomen - gastric bypass, gastric sleeve, small bowel resection and hiatal hernia repair - moves to a platform sold by the company that already supplies its Ethicon staplers and sutures.
Restore Robotics, remanufacturing Intuitive's own EndoWrist instrumentsprivate
The hospital keeps the da Vinci and stops buying new instruments from Intuitive, buying remanufactured ones cleared by the FDA instead. This attacks the 59.8% of revenue that is instruments without touching the installed base at all.
Obesity drugs, principally the GLP-1 classnot listed
The patient does not have the operation. Intuitive's own 10-K says weight loss drugs have reduced the number of bariatric procedures performed on da Vinci, and Medtronic independently reports bariatric declines in its stapling business.
How big it could get
The market and who has signed
The market
America performed about 14.2 million inpatient operations in 2014. At the 15.1% robotic share last measured and $1,830 of instruments each, that is about $3.92B a year. Intuitive's American instrument sales already run near $4.72B, so the count misses a lot: operations outside hospital wards, and all the growth in robotic share since 2018, which nobody has measured since.
Who runs it
Leaders, pay and the cash
Who runs it
Dave Rosa, an engineer with nearly 30 years at Intuitive, became chief executive in July 2025; Gary Guthart, who ran it before him, stays on as full-time chair. Jamie Samath has run finance since 2022. Insiders own well under 1% of the company. The yearly bonus rides on operating profit and on goals the company keeps private; most share awards pay on how many operations are done, none on what each operation earns.
What they did with the money
It bought back $1.44B of stock in the first half, against $181.0M a year earlier, and paid $533.1M to take over its distributors in Italy, Spain and Portugal. It holds $8.63B of cash and investments and borrows nothing.
The last report
The latest report
Intuitive's revenue grew 22%, and its price cut came out at 3% to 5%
What it did to the thesis Mixed quarter
The cut came out at the low end of what we feared, and worldwide growth covers it comfortably. But American growth fell below our line, so the test read against us. Neither half of the price moved enough to change the view.
The report
On the call, management put its instrument price cuts, including China's from November, at 3% to 5% of revenue for each operation once fully in place, with the full effect by the end of 2027. It also settled the hospital class action for $450M.
What's happening now
The background
The price cut is now sized: about 3% to 5% of revenue for each operation, rolling out from the first half of 2027 and complete by the end of 2027. That is less than the 7% of the 2020 programme.
The arithmetic is not frightening: 3.1% to 5.3% more operations would offset it, and operations grew 14% in the September quarter. What is not settled is American growth, 10% in the quarter, and what January's outlook says for 2027.
Where we disagree
Both sides in full
The market
Americans losing health insurance will slow the operations Intuitive is paid for.
We believe
Insurance is the smaller question. Intuitive is cutting its own instrument prices by 3% to 5%, and American operation growth has slowed to 10%.
The argument
The reason for the cut sits in a court docket and a regulator's clearances, not in the growth story management tells: a monopoly finding since withdrawn, a hospital class action heading to trial and a rival cleared to rebuild its instruments.
We would be wrong if American operation growth recovers above 12% in the next quarters while the cut stays at 5% or less.
What it's worth
How we value it
Valued on the analysts' revenue path for three years, each later year closing 30% of the gap to 4%, on official operating profit with stock pay a cost and tax paid in full; the thesis's own evidence is the check on that path.
What the price assumes
Sales growth in the first year, then slowing as ours does, at the same profit per sale.
The price assumed
51.2%
Our estimate
12%
Measured at the close of
6 Nov 2026
The three cases
Bear case$119
Growth runs at half the analysts' path, 6%, 6% and 6%, the margin settles a fifth lower at 24.1%, and new capital earns only the 8% rate: the downturn test.
Our value$213
Revenue grows 12%, 12% and 12% over three years, the analysts' path (C72), then fades toward 4%, closing 30% of the gap each year; the margin moves to 30.2%, the analysts' year-three figure after stock pay.
Bull case$279
Growth runs a quarter above the analysts' path, 15%, 15% and 14%, the margin reaches 33.2%, and new capital earns 15%.
What could go wrong
Every risk
The risks
A deeper cut
A 5-point cut is about $330M a year; management's low end is about $198M. A cut above 5, landing mostly in 2027, bites harder.
Slower American growth
American operation growth slowed to 10%, and more than half of da Vinci operations treat benign conditions that patients can put off.
Rebuilt instruments
Others are cleared to remanufacture Intuitive's instruments, the most profitable line, without touching the robot.
Rival robots
Medtronic names Hugo among its surgical division's growth drivers, and filed it for general surgery in June 2026.
The court
Intuitive agreed to settle the hospital class action for $450M plus terms on outside rebuilders and servicers, pending court approval. The terms are unpublished.
What we still do not know
How much of the 3% to 5% is the longer-life instruments and how much is China's price cut. Intuitive gave one combined figure.
How many complications the robot actually prevents. Nobody outside the company has measured it.
What share of surgery is robotic today. The last outside measure is from 2018.
What changes our view
Every route to a new view
Every route to a new view
→ Neutral
The share price falls to about $256, back within 20% of what we think the business is worth.
→ Attractive
The share price falls to about $170, 80% of what we think the business is worth.
→ Attractive
Intuitive names the price cut, and instrument revenue for each operation falls less than 10% during 2027. da Vinci operations keep growing at 13% a year or more, so volume carries the cut.
The next test
It supports the case if
US da Vinci procedure growth is 11% or better, the 2027 outlook has worldwide procedure growth of 13% or more, and the pricing effect is still 5 points or less.
It pressures the case if
US da Vinci procedure growth is below 10% again, or the 2027 outlook has worldwide growth below 13%, or the pricing effect is sized above 5 points.
We would also be wrong if
A rival robot wins more than a tenth of American robot sales in a year.
American instrument sales stop growing while the number of installed robots still rises.
da Vinci operation growth settles below 10% a year for two quarters running.
The verdict
Scores and how we weighed it
The scores
Growth
4 of 4
Business quality
3 of 4
Financial position
4 of 4
Execution record
3 of 4
Per share capture
4 of 4
Potential
3 of 4
Risk profile
2 of 4
Valuation
1 of 4
Evidence quality
3 of 4
How we weighed it
ValueNegative
The price sits above our value and above the bull case.
BusinessPositive
Most revenue repeats with every operation, and it keeps growing fast.
GrowthMixed
Worldwide growth covers the price cut, but American growth slowed.
RisksNegative
The cut may go deeper, American growth is slowing and rebuilt instruments compete.
RivalsMixed
No filed rival compares directly; against its own normal it is cheaper.
The groupMixed
It sits in none of our ranked groups; hospital spending moves it.
Latest newsMixed
The last report sized the cut at the low end, but American growth read against us.
In plain words
Our estimate of value
We forecast how much cash the business can earn over the next ten years and beyond, then ask what that stream is worth today to an investor who wants an 8% yearly return. We do it three times: a gloomy future, an expected one and a sunny one. We call a share Attractive only when its price is at least 20% below the expected estimate, and Unattractive when it is 20% above.